Scientists have made a significant stride in the fight against cancer with a novel approach to engineering CAR-NK (chimeric antigen receptor natural killer) cells. This breakthrough, developed by researchers at MIT and Harvard Medical School, aims to overcome a common challenge in immunotherapy: the patient’s immune system rejecting the therapeutic cells. The innovation could pave the way for readily available, "off-the-shelf" cancer treatments.Traditional methods for developing CAR-T or CAR-NK cells typically involve a lengthy process of several weeks to engineer and proliferate a patient’s own immune cells. However, this new technique allows for a one-step engineering process that produces CAR-NK.......